Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

 
Web www.patentalert.com

< Methods for identifying compounds capable of supplementing the biological activity of leptin

< Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action

> Compounds and their uses

> 5HT2C receptor modulators
~ 00213